Health care expenditure burden of persisting herpes zoster pain

被引:22
作者
Dworkin, Robert H. [1 ,2 ]
White, Richard [4 ]
O'Connor, Alec B. [3 ]
Hawkins, Kevin [5 ]
机构
[1] Univ Rochester, Sch Med & Dent, Dept Anesthesiol, Rochester, NY 14642 USA
[2] Univ Rochester, Sch Med & Dent, Dept Neurol, Rochester, NY 14642 USA
[3] Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA
[4] Endo Pharmaceut, Chadds Ford, PA USA
[5] Thomson Medstat, Ann Arbor, MI USA
关键词
herpes zoster; postherpetic neuralgia; health care expenditures; cost-effectiveness; treatment; prevention;
D O I
10.1111/j.1526-4637.2006.00196.x
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Objectives. Pain can persist long after the resolution of herpes zoster, but little is known regarding its health care costs. The objective of this study was to determine the health care expenditures associated with persisting pain following herpes zoster by comparing expenditures for patients with postherpetic neuralgia or subacute herpetic neuralgia with a control group without these conditions. Methods. Health care expenditures attributable to persisting pain in herpes zoster patients were calculated using Thomson-Medstat's MarketScan (R) databases to examine commercial, Medicare, and Medicaid claims for inpatient and outpatient services and outpatient prescription drugs. Results. Excess annualized costs were $4,917 for commercially insured patients, $2,696 for Medicare patients, and $9,310 for Medicaid patients. Conclusions. The substantial health care costs associated with persisting pain in herpes zoster have important public health implications given evidence that the incidence of herpes zoster is increasing and that the population is aging in the United States. The results provide a basis for evaluating the cost-effectiveness of existing treatments and emerging prevention strategies.
引用
收藏
页码:348 / 353
页数:6
相关论文
共 17 条
[1]  
Arani RB, 2001, STAT MED, V20, P2429, DOI 10.1002/sim.851
[2]   A PSYCHIATRIC-PATIENT CLASSIFICATION-SYSTEM - AN ALTERNATIVE TO DIAGNOSIS-RELATED GROUPS [J].
ASHCRAFT, MLF ;
FRIES, BE ;
NERENZ, DR ;
FALCON, SP ;
SRIVASTAVA, SV ;
LEE, CZ ;
BERKI, SE ;
ERRERA, P .
MEDICAL CARE, 1989, 27 (05) :543-557
[3]   The lifetime occurrence of Herpes zoster and prevalence of post-herpetic neuralgia: A retrospective survey in an elderly population [J].
Bowsher, D .
EUROPEAN JOURNAL OF PAIN-LONDON, 1999, 3 (04) :335-342
[4]   A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION [J].
CHARLSON, ME ;
POMPEI, P ;
ALES, KL ;
MACKENZIE, CR .
JOURNAL OF CHRONIC DISEASES, 1987, 40 (05) :373-383
[5]   THE COST OF TREATMENT FOR POSTHERPETIC NEURALGIA IN THE UK [J].
DAVIES, L ;
COSSINS, L ;
BOWSHER, D ;
DRUMMOND, M .
PHARMACOECONOMICS, 1994, 6 (02) :142-148
[6]   Clinical applications for change-point analysis of herpes zoster pain [J].
Desmond, RA ;
Weiss, HL ;
Arani, RB ;
Soong, S ;
Wood, MJ ;
Fiddian, PA ;
Gnann, JW ;
Whitley, RJ .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 23 (06) :510-516
[7]   Practice parameter: Treatment of postherpetic neuralgia an evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology [J].
Dubinsky, RM ;
Kabbani, H ;
El-Chami, Z ;
Boutwell, C ;
Ali, H .
NEUROLOGY, 2004, 63 (06) :959-965
[8]   Advances in neuropathic pain - Diagnosis, mechanisms, and treatment recommendations [J].
Dworkin, RH ;
Backonja, M ;
Rowbotham, MC ;
Allen, RR ;
Argoff, CR ;
Bennett, GJ ;
Bushnell, MC ;
Farrar, JT ;
Galer, BS ;
Haythornthwaite, JA ;
Hewitt, DJ ;
Loeser, JD ;
Max, MB ;
Saltarelli, M ;
Schmader, KE ;
Stein, C ;
Thompson, D ;
Turk, DC ;
Wallace, MS ;
Watkins, LR ;
Weinstein, SM .
ARCHIVES OF NEUROLOGY, 2003, 60 (11) :1524-1534
[9]   Treatment and prevention of postherpetic neuralgia [J].
Dworkin, RH ;
Schmader, KE .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (07) :877-882
[10]  
GANGULY R, 2004, ISPOR CONNECTIONS, V10, P2